Skip to main content
. 2016 Nov 4;9:6669–6677. doi: 10.2147/OTT.S112842

Figure 2.

Figure 2

Survival gain for the treatment protocols.

Notes: (A) Survival gain distribution in bevacizumab plus irinotecan group and (B) survival in the dendritic cell immunotherapy group. The two treatments did not show any benefit in survival time for patients with GBM.

Abbreviations: GBM, glioblastoma multiform; SD, standard deviation.